Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
NSI-189
NSI-189 is a benzylpiperazine-aminopyridine neurogenic compound developed by Neuralstem Inc. It was shown to stimulate neurogenesis in the hippocampus and increase hippocampal volume in Phase I trials, representing a novel approach to treating depression and cognitive impairment through structural brain changes.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 1270138-40-3 |
| Molecular Formula | C21H27N3O |
| Class | Other |
| Category | Nootropics |
Mechanism of Action
NSI-189 stimulates neurogenesis in the hippocampus by an incompletely understood mechanism, potentially involving modulation of BDNF, SCF (stem cell factor), and other neurotrophic pathways. In Phase I trials, it increased hippocampal volume by approximately 20% as measured by MRI. It also enhances synaptic plasticity and long-term potentiation. Unlike traditional antidepressants, it appears to work by physically regenerating hippocampal neurons rather than modulating monoamine neurotransmitters.
Dosing Research
Clinical trial doses: 40 mg once daily, 40 mg twice daily, or 40 mg three times daily (40-120 mg/day). Phase II trials used 40 mg and 80 mg daily. Half-life approximately 17-20 hours. Typically used for 12-week cycles in trials. Community users generally follow the 40 mg/day protocol.
Side Effects & Risks
Phase II trials showed generally good tolerability. Reported: headache, dizziness, diarrhea, insomnia. One Phase II trial in MDD did not meet its primary endpoint, raising efficacy questions. Long-term effects of artificially stimulated neurogenesis are unknown. No abuse potential identified but novel mechanism warrants caution.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.